Cystic fibrosis

Cystic fibrosis (CF) is an autosomal recessive, life-limiting, genetically inherited disease. It is a multi-system disorder and results from one of several identified


Read more on Cystic fibrosis



Latest news articles

Added 14 days ago Drug news

European Commission approves label extension for Kalydeco to treat children with cystic fibrosis. Vertex

Vertex Pharmaceuticals (Europe) Limited announced that the European Commission has granted approval of the label extension for kalydeco (ivacaftor) to...

Added 16 days ago Drug news

Two phase III trials of VX-659, tezacaftor + ivacaftor meet primary endpoint in cystic fibrosis.- Vertex Pharma.

Vertex Pharmaceuticals announced that treatment with the triple combination of the next-generation corrector VX-659, tezacaftor and ivacaftor resulted in statistically...

Added 1 month ago Drug news

EU approves Symveki + Kalydeco for cystic fibrosis F508del mutation.- Vertex.

The EU has approved Symveki (tezacaftor 100mg + ivacaftor 150mg) in a combination regimen with Kalydeco (ivacaftor 150mg) to treat...

Search all news articles for Cystic fibrosis

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.

Cushing's Syndrome

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

+ 2 more

Load more


Cystic fibrosis: diagnosis and management

This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life.

Added 6 months ago

European Cystic Fibrosis Society Standards of Care: Best Practice guidelines

Specialised CF care has led to a dramatic improvement in survival in CF: in the last four decades, well above what was seen in the general population over the same period.

Added 4 years ago

End of life care for patients with cystic fibrosis

Palliative care is an approach that improves quality of life for patients and their families facing problems associated with a life-threatening illness. Care planning is particularly important in CF...

Added 7 years ago

Search all guidelines for Cystic fibrosis

Journal articles

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.

Background: Ivacaftor is generally safe and effective in patients aged 2 years and older who have cystic fibrosis and specific CFTR mutations. We assessed its use in children aged 12 to <24 months.

Added 5 months ago

Ivacaftor restores CFTR-dependent sweat gland fluid secretion in cystic fibrosis subjects with S945L alleles.

Background: To determine in vivo effects of CFTR modulators on mutation S945L.

Added 10 months ago

Search all journal articles for Cystic fibrosis


Cystic fibrosis: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
Registration required
Subscription fee
Search all CME for Cystic fibrosis